Research projects from two companies and one academic group comprise the 2014 second half (2H 2014) MJFF Partnering Program selections. These represent some of the most promising projects in the MJFF portfolio, and the Partnering Program presents them directly to larger industry funders that may invest to further their development.

By connecting industry leaders with studies ripe for investment, MJFF aims to push promising research forward, ultimately leading to improved treatments in patients’ hands.

Selected for the 2H 2014 MJFF Partnering Program are:

• NsGene’s encapsulated cell biodelivery of glial cell line-derived neurotrophic factor (GDNF) to protect and repair dopamine neurons
• Brown University Institute for Brain Sciences’ study of bioluminescence to drive optogenetic reactions (making cells sensitive to light) as a novel, minimally invasive method for precise control of brain activity
• Neurolixis’ Phase II clinical study of its selective 5-HTIA agonist NLX-112 to treat levodopa-induced dyskinesia

To learn more about the selected projects, and previously awardees, visit the Partnering Program page.